

Log in



ORIGINAL RESEARCH ARTICLE | VOLUME 88, ISSUE 1, P122-127, JULY 01, 2013

# Acceptability of home use of mifepristone for medical abortion

Yael Swica • Erica Chong   • Tamer Middleton • ... Marji Gold • Courtney A. Schreiber •

Beverly Winikoff • Show all authors

Published: November 23, 2012 • DOI: <https://doi.org/10.1016/j.contraception.2012.10.021>

## Abstract

### Background

Most medical abortion protocols require women to take mifepristone in the doctor's office. We assessed the acceptability of home use of mifepristone among women and their providers.

### Study Design


In this multicenter trial, eligible women requesting termination of early pregnancy ( $n = 301$ ) chose whether to take mifepristone in the office or at home. Data on safety, efficacy, acceptability and disability were collected.


### Results

One hundred thirty-nine women (46%) chose to take mifepristone at home, and 162 (54%) chose office administration. Ninety-five percent of home users said that they would take the mifepristone in the same place in the future. Home users were not more likely to call the doctor's office or make an unplanned visit, and providers would recommend home use again for 95% of patients who chose home use.

### Conclusions

Home administration of mifepristone was safe and acceptable to women and providers in our study.

 n should be offered this choice to allow more flexibility, comfort and privacy in tr  
ances.



## Keywords

[Medical abortion](#) • [Mifepristone](#) • [Home use](#)

To read this article in full you will need to make a payment

[Purchase one-time access](#)

[Subscribe to \*Contraception\*](#)

Already a print subscriber? [Claim online access](#)

Already an online subscriber? [Sign in](#)

Register: [Create an account](#)

Institutional Access: [Sign in to ScienceDirect](#)

## References

1. Danco Laboratories. Mifeprex prescribing information. Rev 4:4/22/09, accessed at [http://www.earlyoptionpill.com/userfiles/file/Mifeprex%20Labeling%204%22%2009\\_Final\\_doc.pdf](http://www.earlyoptionpill.com/userfiles/file/Mifeprex%20Labeling%204%22%2009_Final_doc.pdf).

[View in Article](#) 

[Google Scholar](#)

2. Gomperts R. • Kleiverda G. • Gemzell K. • et al.  
**Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.**  
*BJOG*. 2008; **115**: 1171-1178

 [View in Article](#) 



[Scopus \(38\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

3. Akin A. • Dabash R. • Dilbaz B. • et al.

**Increasing women's choices in medical abortion: a study of misoprostol 400 microg swallowed immediately or held sublingually following 200 mg mifepristone.**

*Eur J Contracept Reprod Health Care.* 2009; **14**: 169-175

[View in Article](#) ^

[Scopus \(19\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

4. Arvidsson C. • Hellborg M. • Gemzell-Danielsson K.

**Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone.**

*Eur J Obstet Gynecol Reprod Biol.* 2005; **123**: 87-91

[View in Article](#) ^

[Scopus \(32\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

5. Beckman L. • Harvey S.

**Experience and acceptability of medical abortion with mifepristone and misoprostol among U.S. women.**

*Wom Health Iss.* 1997; **7**: 253-262

[View in Article](#) ^

[Scopus \(24\)](#) • [PubMed](#) • [Abstract](#) • [Full Text PDF](#) • [Google Scholar](#)

6. Elul B. • Pearlman E. • Sorhaindo A. • et al.

**In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol.**

*J Am Med Wom Assoc.* 2000; **55**: 169-172

[View in Article](#) ^

[PubMed](#) • [Google Scholar](#)

 ala C. • Winikoff B. • Helstrom L. • et al.



**Acceptability of home-use of misoprostol in medical abortion.**

*Contraception*. 2004; **70**: 387-392

[View in Article](#) ^

[Scopus \(58\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

8. Fielding S. • Edmunds E. • Schaff E.

**Having an abortion using mifepristone and home misoprostol: a qualitative analysis of women's experiences.**

*Perspect Sex Reprod Health*. 2002; **34**: 34-40

[View in Article](#) ^

[Scopus \(40\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

9. Ganatra B. • Kalyanwala S. • Elul B. • et al.

**Understanding women's experiences with medical abortion: in-depth interviews with women in two Indian clinics.**

*Global Pub Health*. 2010; **5**: 335-347

[View in Article](#) ^

[Scopus \(13\)](#) • [Crossref](#) • [Google Scholar](#)

10. Hajri S. • Blum J. • Gueddana N. • et al.

**Expanding medical abortion in Tunisia: women's experiences from a multi-site expansion study.**

*Contraception*. 2004; **70**: 487-491

[View in Article](#) ^

[Scopus \(33\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

11. Honkanen H. • Von Hertzen H.

**Users' perspectives on medical abortion in Finland.**

*Contraception*. 2002; **65**: 419-423

[View in Article](#) ^



[Scopus \(23\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)



12. Karki C. • Pokharel H. • Kushwaha A. • et al.  
**Acceptability and feasibility of medical abortion in Nepal.**  
*Int J Gynaecol Obstet.* 2009; **106**: 39-42  
  
[View in Article](#) ^  
[Scopus \(24\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)
  
13. Kiran U. • Amin P. • Penketh R.  
**Self-administration of vaginal misoprostol after mifepristone for termination of pregnancy: patient acceptability.**  
*J Obstet Gynaecol.* 2006; **26**: 679-681  
  
[View in Article](#) ^  
[Scopus \(8\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)
  
14. Lohr P. • Wade J. • Riley L. • et al.  
**Women's opinions on the home management of early medical abortion in the UK.**  
*J Fam Plann Reprod Health Care.* 2010; **36**: 21-25  
  
[View in Article](#) ^  
[Scopus \(24\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)
  
15. Perriera L. • Reeves M. • Chen B. • et al.  
**Feasibility of telephone follow-up after medical abortion.**  
*Contraception.* 2010; **81**: 143-149  
  
[View in Article](#) ^  
[Scopus \(68\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)
  
16. Shah R. • Baji S. • Kalgutkar S.  
**Attitudes about medical abortion among Indian women.**  
*Int J Gynaecol Obstet.* 2005; **89**: 69-70  
  
[View in Article](#) ^  
[Scopus \(7\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)



17. Shochet T. • Trussell J.  
**Determinants of demand: method selection and provider preference among US women seeking abortion services.**  
*Contraception.* 2008; **77**: 397-404
- [View in Article](#) ^
- [Scopus \(26\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)
18. Teal S. • Dempsey-Fanning A. • Westhoff C.  
**Predictors of acceptability of medication abortion.**  
*Contraception.* 2007; **75**: 224-229
- [View in Article](#) ^
- [Scopus \(24\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)
19. Tran N. • Jang M. • Yong S.  
**Feasibility, efficacy, safety, and acceptability of mifepristone-misoprostol for medical abortion in the Democratic People's Republic of Korea.**  
*Int J Obstet Gynecol.* 2010; **109**: 209-212
- [View in Article](#) ^
- [Scopus \(10\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)
20. Winikoff B, Sivin I, Coyaji K et al. The acceptability of medical abortion in China, Cuba and India. *Int Fam Plan Perspect* 1997; 23:73-88, 89.
- [View in Article](#) ^
- [Google Scholar](#)
21. Swica Y. • Raghavan S. • Bracken H. • et al.  
**Review of the literature on patient satisfaction with early medical abortion using mifepristone and misoprostol.**  
*Exp Rev Obstet Gynecol.* 2011; **6**: 451-468

[View in Article](#) ^



[Scopus \(11\)](#) • [Crossref](#) • [Google Scholar](#)



22. Winikoff B.

**Acceptability of medical abortion in early pregnancy.**

*Fam Plann Perspec.* 1995; **185**: 142-148

[View in Article](#) ^

[Scopus \(100\)](#) • [Crossref](#) • [Google Scholar](#)

23. Elul B. • Hajri S. • Ellertson C. • et al.

**Can women in less-developed countries use a simplified medical abortion regimen?.**

*Lancet.* 2001; **357**: 1402

[View in Article](#) ^

[Scopus \(72\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

## Article Info

### Publication History

Published online: November 23, 2012

Accepted: October 19, 2012

Received in revised form: September 15, 2012

Received: June 26, 2012

### Footnotes

◆◆◆ Funds to carry out this study were provided by an anonymous donor without financial interests in the outcome of this study.

### Identification

DOI: <https://doi.org/10.1016/j.contraception.2012.10.021>

### Copyright

© 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

### ScienceDirect

 [this article on ScienceDirect](#)



## Related Articles

[Exploring Canadian women's knowledge of and interest in mifepristone: results from a national qualitative study with abortion patients](#)

*Contraception*, Vol. 94, Issue 2

[In Brief](#) • [Full-Text](#) • [PDF](#)

[A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries](#)

*Contraception*

[In Brief](#) • [Full-Text](#) • [PDF](#)

[Rebound of medication abortion in Texas following updated mifepristone label](#)

*Contraception*, Vol. 99, Issue 5

[In Brief](#) • [Full-Text](#) • [PDF](#)

[Open Access](#)

[If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion](#)

*Contraception*, Vol. 92, Issue 3

[In Brief](#) • [Full-Text](#) • [PDF](#)

[Mifepristone by prescription: not quite a reality in the Northern Territory of Australia](#)

*Contraception*, Vol. 94, Issue 4

[In Brief](#) • [Full-Text](#) • [PDF](#)

[Molecular characterization of PRM-associated endometrial changes, PAEC, following mifepristone treatment](#)

*Contraception*, Vol. 98, Issue 4

[In Brief](#) • [Full-Text](#) • [PDF](#)

 [stone label laws and trends in use: recent experiences in four US states](#)

*ception*, Vol. 92, Issue 3





[In Brief](#) • [Full-Text](#) • [PDF](#)

[Mifepristone antagonization requires real studies to evaluate safety and efficacy](#)

*Contraception*, Vol. 100, Issue 6

[In Brief](#) • [Full-Text](#) • [PDF](#)

[Incidence of uterine rupture in second-trimester abortion with gemeprost alone compared to mifepristone and gemeprost](#)

*Contraception*, Vol. 99, Issue 3

[In Brief](#) • [Full-Text](#) • [PDF](#)

[Reply to: "mifepristone by prescription: not quite a reality in Australia"](#)

*Contraception*, Vol. 94, Issue 4

[In Brief](#) • [Full-Text](#) • [PDF](#)

[Home](#)

[Contraception  
Articles for MOC](#)

[Submit Your  
Manuscript](#)

[Contact  
Information](#)

[Society of Family  
Planning](#)

**ARTICLES AND  
ISSUES**

**FOR AUTHORS**

**JOURNAL INFO**

[Editorial Board](#)

[Society  
Information](#)

[Current Issue](#)

[About Open  
Access](#)

[About Open  
Access](#)

[Info for  
Advertisers](#)

**MORE  
PERIODICALS**

[Online First](#)

[Author Information](#)

[About the Journal](#)

[Pricing](#)

[Find a Periodical](#)

[List of Issues](#)

[Author Services](#)

[Abstracting/Indexi  
ng](#)

[New Content  
Alerts](#)

[Go to Product  
Catalog](#)

[Supplements](#)

[Permissions](#)

[Career  
Opportunities](#)

[Subscribe](#)

[SFP Guidelines](#)

[Researcher  
Academy](#)

**SOCIETY INFO**

**COLLECTIONS**



We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the [use of cookies](#).

Copyright © 2020 Elsevier Inc. except certain content provided by third parties.

